Evidence map›Paper›PMID 24213137›Full record

ArticleCancers2011

NF-kappaB in lung tumorigenesis.

Zhenjian Cai, Kam-Meng Tchou-Wong, William N Rom

Abstract read
In one paragraph

Article in Cancers, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Microbiome in cancer progression and therapy.Current opinion in microbiology · 2020
    Review
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhenjian CaiDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, New York University School of Medicine, 462 First Avenue, NBV 7N24, New York, NY 10016, USA. william.rom@nyumc.org.
Kam-Meng Tchou-Wong
William N Rom

Funding

NYU Lung Cancer Biomarker CenterU01CA086137 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROM, WILLIAM N · 2000 to 2015
$15.3M
Longtitudinal Studies of HIV-Associated Bacterial PneumoniaR01HL090316 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROM, WILLIAM N · 2007 to 2013
$4.2M
Translational Research Training in Environmental MedicineT32ES007267 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROM, WILLIAM N · 1992 to 2013
$4.0M
NCI NIH HHS U01 CA086137NHLBI NIH HHS R01 HL090316NIEHS NIH HHS T32 ES007267
6 · The paper itself

Abstract

The development of lung cancer in humans can be divided into three steps: initiation, promotion and progression. This process is driven by alterations in related signal transduction pathways. These pathways signal the aberrant activation of NF-kappaB, a transcription factor that regulates the expression of genes important for lung tumorigenesis. Our current knowledge about the role of the NF-kappaB signaling pathway in the development of lung cancer has been bolstered by animal models demonstrating the connection between K-ras and tobacco induced lung transformation with NF-kappaB. Activation of downstream genes leads to cell proliferation, inhibition of apoptosis, angiogenesis, inflammation, invasion, and metastasis.

Identifiers

PMID24213137
PMCPMC3763422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.